Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563868 · ClinicalTrials.gov registry record · NA
Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression
A NA study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT07563868: Recruiting NA study, sponsored by Massachusetts General Hospital.
NCT07563868 is a NA study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07563868, a NA study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic. Participation in the study will involve adding coaching sessions to your existing ketamine maintenance treatment.
Interventions
- BEHAVIORAL Psychedelic Integration Coaching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07563868
The ClinicalTrials.gov registry entry for NCT07563868 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psychedelic Integration Coaching is the first listed.
NCT07563868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07563868 about?
NCT07563868 is a clinical study titled "Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression". This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participant...
What is the current status of trial NCT07563868?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2028-04-01.
What interventions are being tested in trial NCT07563868?
The interventions under investigation include: Psychedelic Integration Coaching (BEHAVIORAL).
Who is sponsoring clinical trial NCT07563868?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.